Advanced search: Search from
Select basic information for advanced search
| Free word |
|---|
Rchr
J-GLOBAL ID：200901013303807147
Update date: Feb. 28, 2025 Sasada Tetsuro
ササダ テツロウ | Sasada Tetsuro
Kanagawa Cancer Center Research Institute, Cancer Vaccine and Immunotherapy Center
About Kanagawa Cancer Center Research Institute, Cancer Vaccine and Immunotherapy Center
Job title： Department director
Homepage URL (1)： http://kcch.kanagawa-pho.jp/kccri/
Research field (4)：
Tumor diagnostics and therapeutics
, Digestive surgery
, General surgery, pediatric surgery
, Immunology
Research keywords (7)：
Tumor immunolgy
, Cancer immunotherapy
, Personalized immunotherapy
, Cancer vaccine
, Neoantigen
, Biomarker
, Chimeric antigen receptor (CAR) -T cell therapy
Research theme for competitive and other funds (15)： - 2023 - 2025 ペプチドミクス解析とシングルセルTCR解析を用いたネオアンチゲン同定法の確立
- 2022 - 2025 Establishment of an AI-based platform for predicting response to cancer immunotherapy
- 2021 - 2024 Identification of cancer-specific neoantigens in organoid culture
- 2019 - 2024 アミノ酸プロファイルによるがん免疫微小環境の代謝リプログラミング評価とがん免疫治療患者層別化技術の開発
- 2018 - 2020 Analysis of B cell repertoires and their antigen specificity in peripheral blood from cancer patients undergoing anti-PD-1 antibody therapy.
Show all
- Daiki Murata, Koichi Azuma, Yuuya Nishii, Kenta Murotani, Goushi Matama, Akihiko Kawahara, Takaaki Tokito, Tetsuro Sasada, Tomoaki Hoshino. The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer. Chemotherapy. 2025. 1-7
- Yasunobu Mano, Yuka Igarashi, Keisuke Komori, Itaru Hashimoto, Hayato Watanabe, Kosuke Takahashi, Kazuki Kano, Hirohito Fujikawa, Takanobu Yamada, Hidetomo Himuro, et al. Characteristics and clinical significance of immune cells in omental milky spots of patients with gastric cancer. Frontiers in immunology. 2025. 16. 1521278-1521278
- Daiki Murata, Koichi Azuma, Kenta Murotani, Akihiko Kawahara, Yuuya Nishii, Takaaki Tokito, Tetsuro Sasada, Tomoaki Hoshino. Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy. Cancer immunology, immunotherapy : CII. 2024. 73. 11. 214-214
- Shun Horaguchi, Yoshiro Nakahara, Yuka Igarashi, Taku Kouro, Feifei Wei, Kenta Murotani, Seiichi Udagawa, Naoko Higashijima, Norikazu Matsuo, Shuji Murakami, et al. Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Biomedicines. 2024. 12. 8
- Kazumasa Sekihara, Hidetomo Himuro, Soji Toda, Nao Saito, Ryoichi Hirayama, Nobuyasu Suganuma, Tetsuro Sasada, Daisuke Hoshino. Recent Trends and Potential of Radiotherapy in the Treatment of Anaplastic Thyroid Cancer. Biomedicines. 2024. 12. 6
- 氷室秀知, 眞野恭伸, 魏菲菲, 神谷郁也, 紅露拓, 辻嘉代子, 駒橋充, 駒橋充, 笹田哲朗. Effect of Japanese herbal medicine ′′Tsudousan′′ on abscopal effect. 日本癌学会学術総会抄録集(Web). 2024. 83rd
- 紅露拓, 紅露拓, 眞野恭伸, 眞野恭伸, 笠島理加, 星野大輔, 辻祥太郎, 今井浩三, 笹田哲朗, 笹田哲朗. Influence of CAR co-stimulatory domains on downstream signaling and CAR-T cell exhaustion. 日本癌学会学術総会抄録集(Web). 2024. 83rd
- 氷室秀知, 眞野恭伸, 魏菲菲, 紅露拓, 神谷郁也, 辻嘉代子, 駒橋充, 駒橋充, 笹田哲朗. 漢方方剤「通導散」のアブスコパル効果への影響についての検討. 日本がん免疫学会総会プログラム・抄録集. 2024. 28th
- 紅露拓, 紅露拓, 眞野恭伸, 眞野恭伸, 笠島理加, 星野大輔, 辻祥太郎, 今井浩三, 笹田哲朗, 笹田哲朗. Conversion of CD28 co-stimulatory domain to 4-1 BB in self-activating CAR results in alteration of tonic signaling from NFAT to NFκB. 日本がん免疫学会総会プログラム・抄録集. 2024. 28th
- 洞口 俊, 笹田 哲朗. がん免疫療法の現状と展望. 日本小児血液・がん学会雑誌. 2023. 60. 3. 192-198
- がん免疫療法の予後予測のためのバイオマーカー
- 免疫チェックポイント阻害剤治療の治療選択を補助する指標の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、評価システム、及び端末装置
- がん免疫療法の治療効果予測に有用な遺伝子多型
- 新規ネオアンチゲン及びそれらを用いたがん免疫治療薬
- Antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation
- プレシジョン・メディシン ~ビッグデータの構築・分析から臨床応用・課題まで~
エヌ・ティー・エス 2018 - がん治療で起こる副作用・合併症の治療法と薬剤開発
技術情報協会 2018 - 疾患・病態検査・診断法の開発
技術情報協会 2017 - ペプチド医薬品のスクリーニング・安定化・製剤化技術
技術情報協会 2017 - Cancer Immunology - Cancer Immunotherapy for organ-specific tumors.
Springer-Verlag Berlin Heidelberg 2015
- - 1997 Kyoto University Graduate School of Medicine Pathology
- - 1987 Kyoto University Faculty of Medicine Department of Medical Science
- Doctor (Kyoto University)
- 2014/11 - 現在 Kanagawa Cancer Center Cancer Vaccine and Immunotherapy Center, Research Institute Director
- 2010/04 - 2014/11 Kurume University School of Medicine Department of Immunology and Immunotherapy Associate Professor
- 2006/04 - 2010/03 Dana-Farber Cancer Institute, Harvard University Cancer Vaccine Center Director of Immune Assessment Core
- 2001/11 - 2006/03 Tazuke-Kofukai Research Institute Kitano Hospital Department of Surgery Vice director
- 2001/07 - 2001/11 Kyoto University Hospital Department of Surgery Clinical Fellow
Show all
- - 現在 日本免疫学会 評議員
- - 現在 日本癌学会 評議員
- - 現在 日本がん免疫学会 評議員
- - 現在 日本遺伝子治療学会 評議員
- 2016 - 内藤記念科学振興財団 奨励金・研究助成助成金
- 2015 - 新日本先進医療研究財団 研究助成金
- 2014 - 東京生化学研究会 研究助成金
- 2013 - 多発性骨髄腫 研究助成
- 2013 - がん集学的治療研究財団 第33回一般研究助成
Show all
American Society of Clinical Oncology
, Society for Immunotherapy of Cancer
, American Association for Cancer Research
, Japanese Association of Cancer Immunology
, Japan Society of Gene and Cell Therapy
, Japanese Society for Immunology
, Japan Society of Clinical Oncology
, Japanese Cancer Association
, Japanese Society of Gastroenterological Surgery
, Japan Surgical Society
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.
Return to Previous Page
